The Cardiac Late Sodium Channel Current is a Molecular Target for the Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin
Sodium/glucose co-transporter 2 SGLT2 inhibitors exert cardioprotective effects against heart failure in diabetes patients. There is intense interest to identify the underlying molecular mechanisms that afford this protection. SGLT2 inhibitors reduced late-INa in cardiomyocytes from mice with heart failure. In an acute model of myocardial injury, perfusion of isolated mouse hearts with empagliflozin prevented activation of the cardiac NLRP3 inflammasome.

Related Post